A biopharmaceutical company that pioneers antisense and RNA-targeting drug technology to develop treatments for cardiovascular, neurological and rare diseases.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Ancora | 38 | Added +10% | 2,342 | $185,276 | 0.0% |
| Bridgewater | 49 | Added +55% | 67,706 | $5,356,222 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.